Last updated: 2026-09-24 23:28:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Biomea Fusion, Inc. (BMEA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1,49, with a market capitalization of $123,22M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,87 to $2,99. This page covers its latest market performance, valuation, price trends and company information.
$123,22M | |
$1,46 | |
$43,69 | |
$0,87 | |
$1,44 | |
2,10M | |
1,45M | |
-- | |
$2,99 | |
$0,87 | |
-- | |
-- |
Biomea Fusion, Inc. (BMEA) is trading at $1,49 in after-hours trading as of 2026-09-24 23:27:00, up 3,47% ($0,05) from the regular-session close of $1,44.
After-hours trading shows how investors are pricing BMEA after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Biomea Fusion, Inc. (BMEA) moved from $1,80 to $1,49, representing a decline of 17,50% ($0,31).
The stock traded between $1,35 and $1,93 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2,77 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 28,9%
BMEA is currently trading at $1,49, placing it 28,9% of the way from its 52-week low of $0,87 to its 52-week high of $2,99. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 37 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Biomea Fusion, Inc. (BMEA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.